Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2

Dong, Shuying; Li, Zhuxin; Kong, Jian; Wu, Shilun; Gao, Jun; Sun, Wenbing

doi:10.1080/02656736.2022.2093995

Cited by 13 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, whether Akt/HIF-1α axis is involved in the progression of residual HCC after RFA by modulating Ang-1 or Ang-2 was still unclear. A more recent study indicated that IRFA was simulated using a water bath and promoted tumor growth and angiogenesis of HCC in vitro and in vivo ( Dong et al, 2022 ). The above phenomenon could be suppressed by arsenic trioxide (ATO) ( Dong et al, 2022 ).…”

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

“…A more recent study indicated that IRFA was simulated using a water bath and promoted tumor growth and angiogenesis of HCC in vitro and in vivo ( Dong et al, 2022 ). The above phenomenon could be suppressed by arsenic trioxide (ATO) ( Dong et al, 2022 ). Furthermore, higher levels of Ang-1, Ang-2, and p-Tie2 were detected in a conditioned medium from RFA-treated than from untreated HCC cells ( Dong et al, 2022 ).…”

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

“…The above phenomenon could be suppressed by arsenic trioxide (ATO) ( Dong et al, 2022 ). Furthermore, higher levels of Ang-1, Ang-2, and p-Tie2 were detected in a conditioned medium from RFA-treated than from untreated HCC cells ( Dong et al, 2022 ). The expression of HIF-1α and p-Akt were also upregulated following RFA in HCC cells ( Dong et al, 2022 ).…”

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

“…Furthermore, higher levels of Ang-1, Ang-2, and p-Tie2 were detected in a conditioned medium from RFA-treated than from untreated HCC cells ( Dong et al, 2022 ). The expression of HIF-1α and p-Akt were also upregulated following RFA in HCC cells ( Dong et al, 2022 ). The levels of Ang-1, Ang-2, p-Tie2, HIF-1α, and p-Akt were suppressed by ATO ( Dong et al, 2022 ).…”

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

See 3 more Smart Citations

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Xiao

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common digestive malignancies. HCC It ranges as the fifth most common cause of cancer mortality worldwide. While The prognosis of metastatic or advanced HCC is still quite poor. Recently, locoregional treatment, especially local ablation therapies, plays an important role in the treatment of HCC. Radiofrequency ablation (RFA) and high-intensity focused ultrasound (HIFU) ablation are the most common-used methods effective and feasible for treating HCC. However, the molecular mechanisms underlying the actions of ablation in the treatments for HCC and the HCC recurrence after ablation still are poorly understood. Hypoxia-inducible factor (HIF), the key gene switch for adaptive responses to hypoxia, has been found to play an essential role in the rapid aggressive recurrence of HCC after ablation treatment. In this review, we summarized the current evidence of the roles of HIF in the treatment of HCC with ablation. Fifteen relevant studies were included and further analyzed. Among them, three clinical studies suggested that HIF-1α might serve as a crucial role in the RAF treatment of HCC or the local recurrence of HCC after RFA. The remainder included experimental studies demonstrated that HIF-1, 2α might target the different molecules (e.g., BNIP3, CA-IX, and arginase-1) and signaling cascades (e.g., VEGFA/EphA2 pathway), constituting a complex network that promoted HCC invasion and metastasis after ablation. Currently, the inhibitors of HIF have been developed, providing important proof of targeting HIF for the prevention of HCC recurrence after IRFA and HIFU ablation. Further confirmation by prospective clinical and in-depth experimental studies is still warranted to illustrate the effects of HIF in HCC recurrence followed ablation treatment in the future.

show abstract

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

Section: Ato Inhibits Tumor Growth and Angiogenesis Of Hcc By Blockin...mentioning

confidence: 99%

See 2 more Smart Citations

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Xiao

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Dong et al. ( 104 ) demonstrated that ATO blocked the paracrine signaling of Ang-1 and Ang-2 by inhibiting p-Akt/Hif-1a and further suppressed angiogenesis of HCC after insufficient RFA. Chen et al.…”

Section: Strategies To Prevent Progression Of Hcc After Rfamentioning

confidence: 99%

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Yao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains an important disease for health care systems in view of its high morbidity, mortality, and increasing incidence worldwide. Radiofrequency ablation (RFA) is preferred to surgery as a local treatment for HCC because it is safer, less traumatic, less painful, better tolerated, causes fewer adverse reactions, and allows more rapid postoperative recovery. The biggest shortcoming of RFA when used to treat HCC is the high incidence of residual tumor, which is often attributed to the vascular thermal deposition effect, the wide infiltration zone of peripheral venules, and the distance between satellite foci and the main focus of the cancer. Recurrence and progression of the residual tumor is the most important determinant of the prognosis. Therefore, it is important to be aware of the risk of recurrence and to improve the efficacy of RFA. This review summarizes the relevant literature and the possible mechanisms involved in progression of HCC after RFA. Current studies have demonstrated that multimodal treatments which RFA combined with other anti-cancer approaches can prevent progression of HCC after RFA.

show abstract

Radiofrequency ablation: mechanisms and clinical applications

Wu,

Zhou,

Huang

et al. 2024

MedComm

View full text Add to dashboard Cite

Radiofrequency ablation (RFA), a form of thermal ablation, employs localized heat to induce protein denaturation in tissue cells, resulting in cell death. It has emerged as a viable treatment option for patients who are ineligible for surgery in various diseases, particularly liver cancer and other tumor‐related conditions. In addition to directly eliminating tumor cells, RFA also induces alterations in the infiltrating cells within the tumor microenvironment (TME), which can significantly impact treatment outcomes. Moreover, incomplete RFA (iRFA) may lead to tumor recurrence and metastasis. The current challenge is to enhance the efficacy of RFA by elucidating its underlying mechanisms. This review discusses the clinical applications of RFA in treating various diseases and the mechanisms that contribute to the survival and invasion of tumor cells following iRFA, including the roles of heat shock proteins, hypoxia, and autophagy. Additionally, we analyze‌ the changes occurring in infiltrating cells within the TME after iRFA. Finally, we provide a comprehensive summary of clinical trials involving RFA in conjunction with other treatment modalities in the field of cancer therapy, aiming to offer novel insights and references for improving the effectiveness of RFA.

show abstract

Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2

Cited by 13 publications

References 30 publications

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Radiofrequency ablation: mechanisms and clinical applications

Contact Info

Product

Resources

About